Effects of CYP3A5 genotypes, ABCB1 C3435T and G2677T/A polymorphism on pharmacokinetics of Tacrolimus in Chinese adult liver transplant patients

Xenobiotica

Volumn 45, Issue 9, 2015, Pages 840-846

  Zhu, Liqin ^a   Yang, Jianwei ^b   Zhang, Yuan ^a   Jing, Yaqing ^b   Zhang, Yanwen ^b   Li, Guang ^b  

^a TIANJIN FIRST CENTRAL HOSPITAL   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

ABCB1 C3435T; CYP3A5; G2677T A; liver transplant; tacrolimus

Indexed keywords

ALKALINE PHOSPHATASE; CORTICOSTEROID; CYTOCHROME P450 3A5; GENOMIC DNA; HEMOGLOBIN; MULTIDRUG RESISTANCE PROTEIN 1; MYCOPHENOLATE MOFETIL; TACROLIMUS; ABCB1 PROTEIN, HUMAN; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450 3A; MULTIDRUG RESISTANCE PROTEIN;

ABSORPTION RATE CONSTANT; ADULT; AGED; ARTICLE; CHINESE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG MONITORING; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; GRAFT RECIPIENT; HAPLOTYPE; HEMATOCRIT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER FUNCTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; UREA NITROGEN BLOOD LEVEL; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MODEL; DEMOGRAPHY; GENE FREQUENCY; GENETICS; MIDDLE AGED; REPRODUCIBILITY; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CYTOCHROME P-450 CYP3A; DEMOGRAPHY; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; P-GLYCOPROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; REPRODUCIBILITY OF RESULTS; TACROLIMUS;

EID: 84940023806     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2015.1021733     Document Type: Article

References (40)

1. Antignac M, Hulot JS, Boleslawski E, et al. (2005). Population pharmacokinetics of tacrolimus in full liver transplant patients: modeling of the post-operative clearance. Eur J Clin Phamacol 61: 409-16
2. Brendel K, Dartois C, Comets E, et al. (2007). Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004. Clin Pharmacokinet 46: 221-34
3. Chandel N, Aggarwal PK, Minz M, et al. (2009). CYP3A5 1/3 genotype influence the blood concentration of tacrolimus in response to metabolic inhibition by ketoconazole. Pharmacogenet Genom 19: 458-63
4. Cho JH, Yoon YD, Park JY, et al. (2012). Impact of cyochrome P450 3A and ATP-binding cassette subfamily B member 1 polymorphisms on tacrolimus dose-adjusted trough concentrations among Korean renal transplant recipients. Transplant Proc 44: 109-14
5. Dirks NL, Huth B, Yates CR, Meibohm B. (2004). Pharmacokinetics of immunosuppressants: a prespective on ethnic differencses. Int J Clin Pharmacol Ther 42: 701-18
6. First MR. (2004). Tacrolimus based immunosuppression. J Nephrol 17: S25-31
7. Fukudo M, Yano I, Masuda S, et al. (2006). Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living-donor liver transplant recipients. Clin Pharmacol Ther 80: 331-45
8. Fukudo M, Yano I, Yoshimura A, et al. (2008). Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients. Pharmacogenet Genomics 18: 413-23
9. Gijsen VM, Madadi P, Dube MP, et al. (2012). Tacrolimus-induced nephrotoxicity and genetic variability: a review. Ann Transplant 17: 111-21
10. Han N, Yun HY, Hong JY, et al. (2013). Prediction of the tacrolimus population pharmacokinetic parameters according to CYP3A5 genotype and clinical factors using NONMEM in adult kidney transplant recipients. Eur J Clin Pharmacol 69: 53-63
11. Hesselink DA, van Gelder T, van Schaik RH. (2005). The pharmacokinetics of calcineurin inhibitors: one step closer toward individualized immunosuppression? Pharmacogenomics 6: 323-37
12. Hu RH, Lee PH, Tsai MK. (2000). Clinical influencing factors for daily dose, trough level and relative clearance of tacrolimus in renal transplant recipients. Transplant Proc 32: 1689-92
13. Ji E, Choi L, Suh KS, et al. (2012). Combination effect of intestinal and hepatic CYP3A5 genotypes on tacrolimus pharmacokinetics in recipients of living donor liver transplantation. Transplantation 94: 866-72
14. Jolling K, Perez Ruixo JJ, Hemeryck A, et al. (2005). Mixed-effects modeling of the interspecies pharmacokinetic scaling of pegylated human erythropoietin. Eur J Pharm Sci 24: 465-75
15. Jusko WJ, Piekoszewski W, Klintmalm GB, et al. (1995). Pharmacokinetics of tacrolimus in liver transplant patients. Clin Pharmacol Ther 57: 281-90
16. Kauffman RE, Kearns GL. (1992). Pharmacokinetic studies in paediatric patients. Clinical and ethical considerations. Clin Pharmacokinet 23: 10-29
17. Lindbom L, Pihlgren J, Jonsson EN. (2005). PsN-Toolkit-a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Computer Methods Programs Biomed 79: 241-57
18. Macphee IA. (2010). Use of pharmacogenetics to optimize immunosuppressive therapy. Ther Drug Monit 32: 261-4
19. Miao LY, Huang CR, How JQ, Qian MY. (2008). Association study of ABCB1 and CYP3A5 genepolymorphism with sirolimus trough concentration and dose requirements in Chinese renal transplant recipients. Biopharm Drug Dispos 29: 1-5
20. Min SI, Kim SY, Ahn SH, et al. (2010). CYP3A5∗1 ALLELE: impacts on early acute rejection and graft function in tacrolimus-based renal transplant recipients. Transplantation 90: 1394-400
21. Musuamba FT, Mourad M, Hanfroid V, et al. (2009). Time of drug administration, CYP3A5 and ABCB1 genetypes, and analytical method influence tacrolimus pharmacokinetics: a population pharmacokinetic study. Ther Drug Monit 31: 734-42
22. Oteo I, Lukas JC, Leal N, et al. (2013). Tacrolimus pharmacokinetics in the early post-liver transplantation period and clinical applicability via Bayesian prediction. Eur J Clin Pharmacol 69: 65-74
23. Sam WJ, Tham LS, Holmes MJ, et al. (2006). Population pharmacokinetics of tacrolimus in whole blood and plasma in Asian liver transplant patients. Clin Pharmacokinet 45: 59-75
24. Scheiner LB, Beal SL. (1981). Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 9: 503-12
25. Shi XJ, Geng F, Jiao Z, et al. (2011). Association of ABB1, CYP3A4∗18B and CYP3A5∗3 genotypes with the pharmacokinetics of tacrolimus in healthy Chinese subjects: a population pharmacokinetic analysis. J Clin Pharm Ther 36: 614-24
26. Staatz CE, Gooddman LK, Tett SE. (2010a). Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors. Part I. Clin Pharmacokinet 49: 141-75
27. Staatz CE, Goodman LK, Tett SE. (2010 b). Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors. Part II. Clinical Pharmacokinet 49: 207-21
28. Staatz CE, Willis C, Taylor PJ, et al. (2003). Toward better outcomes with tacrolimua therapy: population pharmacokinetics and individual dosage prediction in adult liver transplant. Liver Transpl 9: 130-7
29. Thervet E, Loriot MA, Barbier S, et al. (2010). Optimization of initial tacrolimus dose using pharmacokinetic testing. Clin Pharmacol Therapeut 87: 721-6
30. Undre NA, Schafer A. (1998). Factors affecting the pharmacokinetics of tacrolimus in the first year after renal transplantation. European Tacrolimus Multicentre Renal Study Group. Transplant Proc 30: 1261-3
31. Van Rossum HH, Press RR, Den Hartigh J, et al. (2010). A call for advanced pharmacokinetic and pharmacodynamic montoring to guide calcineurin inhibitor dosing in renal transplant recipients. Clin Chem 56: 723-9
32. Venkataramanan R, Swaminathan A, Prasad T, et al. (1995). Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet 29: 404-30
33. Viterbo VG, Scohy A, Verbeeck RK, et al. (2013). Population pharmacokinetic analysis of tacrolimus in the first year after pediatric liver transplantation. Eur J Clin Pharmacol 69: 1533-42
34. Wallemacq P, Armstrong VW, Brunet M, et al. (2009). Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference. Ther Drug Monit 31: 139-52
35. Wei-Lin W, Jing J, Shu-sen Z, et al. (2006). Tacrolimus dose requirement in relation to donor and recipient ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients. Liver Transpl 12: 775-80
36. Xue L, Zhang H, Ma S, et al. (2011). Population pharmcokinetics and pharmacogenetics of tacrolimus in healthy Chinese volunteers. Pharmacology 88: 288-94
37. Yasuhara M, Hashida T, Toraguchi M, et al. (1995). Pharmacokinetics and pharmacodynamics of FK506 in pediatric patients receiving living-related donor liver transplantations. Transplant Proc 27: 1108-10
38. Zahir H, McLachlan AJ, Nelson A, et al. (2005). Population pharmacokinetic estimation of tacrolimus apparent clearance in adult liver transplant recipients. Ther Drug Monit 27: 422-30
39. Zhu L, Wang H, Sun X, et al. (2014). The population pharmacokinetic models of tacrolimus in Chinese adult liver transplantation patients. J Pharm 2014: Article ID 713650, 7 pages
40. Zuo XC, Ng CM, Barrett JS, et al. (2013). Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis. Pharmacokinet Genom 23: 251-61